AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

75 76 Next >

Artelo Biosciences Analyst See It As An Emerging Biotech ↗

July 08, 2025

Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its candidate for depression.

Via Benzinga

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

July 08, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

NIKE, Datadog And Snap Are Among Top 11 Large Cap Gainers Last Week (June 30-July 4): Are The Others In Your Portfolio? ↗

July 06, 2025

11 best performing large-cap stocks last week, including Symbotic, Nike, First Solar, Datadog, HPE, Summit Therapeutics, Carnival, POSCO, Wynn Resorts, SharkNinja, and Snap

Via Benzinga

Price Over Earnings Overview: AstraZeneca ↗

July 02, 2025

Via Benzinga

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

July 08, 2025

From FN Media Group LLC

Via GlobeNewswire

Why AstraZeneca Stock Got Thumped on Thursday ↗

July 03, 2025

Via The Motley Fool

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗

July 03, 2025

Via Benzinga

AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report ↗

July 03, 2025

While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that...

Via Stocktwits

Why AstraZeneca Stock Topped the Market on Tuesday ↗

July 01, 2025

Via The Motley Fool

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

June 28, 2025

Via The Motley Fool

Topics Intellectual Property

Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. ↗

June 26, 2025

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.

Via Investor's Business Daily

Topics Government

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

June 24, 2025

From AstraZeneca

Via Business Wire

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer ↗

June 24, 2025

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

Via Benzinga

Is the Market Bullish or Bearish on AstraZeneca? ↗

June 20, 2025

Via Benzinga

AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion ↗

June 13, 2025

AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.

Via Benzinga

AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer ↗

June 13, 2025

CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales...

Via Stocktwits

Topics Artificial Intelligence

Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder ↗

June 12, 2025

Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 12, 2025

Via Benzinga

IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

June 12, 2025

IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals.

Via MarketBeat

Jensen Huang's Quantum Support Boosts IonQ's Growth Plans: Nvidia Partnership, Oxford Ionics Deal Lead Needham To Reiterate 'Buy' ↗

June 12, 2025

Needham maintained its 'buy' rating on IonQ, saying that the Oxford Ionics acquisition could propel 2 million physical qubits by 2030.

Via Benzinga

What's Going On With IonQ Shares Monday? ↗

June 09, 2025

IonQ shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca, Amazon Web Services and Nvidia.

Via Benzinga

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season ↗

June 09, 2025

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Via Benzinga

Is D-Wave Quantum a Better Quantum Computing Stock to Buy Than IonQ? ↗

June 09, 2025

Via The Motley Fool

AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO ↗

June 02, 2025

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.

Via Benzinga

How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma ↗

June 02, 2025

Three new cancer drugs could help make a dent in the company's ambitious plans for 2030.

Via Investor's Business Daily

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

June 02, 2025

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

June 01, 2025

From AstraZeneca

Via Business Wire

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

June 01, 2025

From AstraZeneca

Via Business Wire

Why Tempus AI Stock Plummeted This Week ↗

May 30, 2025

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.